Virtual Library

Start Your Search

Jonathon Hill

Author of

  • +

    P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.01-35 - Outcomes in Advanced Non-Small Cell Lung Cancer After Discontinuation of PD-1 Checkpoint Inhibitor Due to Toxicity. A Retrospective Study (ID 13628)

      12:00 - 13:30  |  Presenting Author(s): Jonathon Hill

      • Abstract
      • Slides


      Programmed cell death ligand (PD-1) checkpoint inhibitors have been shown to improve survival in advanced non-small cell lung cancer. Although immune-related adverse events from single agent anti PD-1 or PDL-1 are manageable, severe toxicities require treatment discontinuation. There are limited data on patient outcomes after treatment discontinuation and the necessary cessation of treatment can cause concern of disease control for the patient and clinician. This retrospective study examined disease outcomes in patients after discontinuation of PD-1 checkpoint inhibitor due to toxicity.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Patients treated with pembrolizumab or nivolumab monotherapy for advanced non-small cell lung cancer at our cancer centre were identified. A retrospective review of electronic and paper records was performed. Information including patient baseline characteristics, progression- free survival, overall survival, toxicity leading to treatment discontinuation and time to progression after treatment cessation were obtained. Imaging was reviewed to confirm events of disease progression.

      4c3880bb027f159e801041b1021e88e8 Result

      54 advanced non-small cell lung cancer patients treated between 2012 and 2017 with single agent pembrolizumab or nivolumab were included in the analysis. 8 (14.8%) patients experienced toxicity necessitating treatment discontinuation. Baseline characteristics including age, ECOG performance status, prior lines of therapy and smoking status were similar in patients with or without severe immune-related toxicities. Pneumonitis was the most common toxicity requiring treatment cessation (n=4). Other toxicities included colitis (n=1), vasculitis (n=1), myositis (n=1) and bullous pemphigoid (n=1). The overall survival at 1 year was 42.6% for all patients versus 37.5% for patients with toxicities requiring treatment cessation. 2 of the patients with pneumonitis died as a result of this toxicity prior to achieving disease control. The patient with bullous pemphigoid and those survived pneumonitis had not experienced disease progression at time of analysis (all censored, alive and progression free for minimum of 6 months after treatment discontinuation). Time to progression was <5 months in the patients with colitis, myositis and vasculitis.

      8eea62084ca7e541d918e823422bd82e Conclusion

      With the limitations of this small study at a single site, patients requiring treatment cessation from toxicity had comparable progression-free and overall survival to those without severe toxicities. The risk of Grade 5 immune- related pneumonitis might have contributed to the numerically lower survival rates in the group that experienced toxicity. Prolonged disease control was observed in patients who survived pneumonitis despite treatment discontinuation.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.